



Curriculum Vitae

Personal information Erik Briers

Work experience

1. Employer: Several
 - Start date: 091972
 - End date: 061978
 - Position: Lecturer of chemistry / researcher
 - Activities: Teaching chemistry to professional bachelors level, for students training to become teachers, teacher of chemistry _ physics at high school level, PHD research at KU_Leuven Belgium
 - Country: Belgium
2. Employer: Central Laboratory Antwerp
 - Start date: 061979
 - End date: 101980
 - Position: Head of medical biochemistry laboratory
 - Activities: Manager of the medical biochemistry, responsibility for new technologies and quality assurance
 - Country: Belgium
3. Employer: bioMérieux
 - Start date: 101980
 - End date: 091982
 - Position: Head of scientific services
 - Activities: Head of scientific services for bioMérieux for its Benelux operations, responsible for implementing medical analysis on equipment, assistance in quality assurance etc.
 - Country: Belgium
4. Employer: ECO_BIO
 - Start date: 101982
 - End date: 101990
 - Position: Founder and CEO
 - Activities: Founder and CEO of a biotech company active in in vitro diagnostics main fields medical microbiology and immunology. Developed a detection assay for systemic fungal (aspergillosis) infections [only available assay today].
 - Country: Belgium
5. Employer: Beta_Ventures
 - Start date: 101990
 - End date: 122017
 - Position: Founder and CEO
 - Activities: Founder and CEO of Beta Ventures, main activities are publishing and editing Focus Diagnostica a magazine in in vitro diagnostics, organising continued education for clinical pathologists [with accreditation], consulting with national in vitro diagnostic companies. Consulting with European Patient organisations to assist them in daily management [ex. EPPOSI]
 - Country: Belgium
6. Employer: KU Leuven
 - Start date: 032009
 - End date: 062016
 - Position: Guest Lecturer
 - Activities: Guest lecturer on principles of immunology, in vivo use (vaccination, immunotherapy), in vitro use of antibodies in the medical laboratory and drug design in the treatment of cancer [prostate cancer as a model]
 - Country: Belgium
7. Employer: European Cancer Patient Coalition
 - Start date: 062012
 - End date: 072013
 - Position: Executive director
 - Activities: Executive director for ECPC
 - Country: Belgium
8. Employer: EPPOSI
 - Start date: 022014
 - End date: 122014
 - Position: Executive Director ad interim
 - Activities: Executive director part time and ad interim
 - Country: Belgium

Education and training

1. Subject: KU Leuven
 - Start date: 091969
 - End date: 071973
 - Qualification: Master of Chemistry
 - Organisation: Macromolecular and organic chemistry Plus all other basic chemistry subject as per curriculum
 - Country: Belgium
2. Subject: KU Leuven
 - Start date: 091973

- End date: 071974
 - Qualification: Teacher certificat for high school level teaching
 - Organisation: Teaching skills on scientific curriculum [chemistry, physics, biology...] for high school level students
 - Country: Belgium
3. Subject: KU Leuven
- Start date: 081973
 - End date: 031979
 - Qualification: Doctor of science _ chemistry [PHD]
 - Organisation: PHD in macromolecular and organic chemistry
 - Country: Belgium
4. Subject: KU Leuven [HIVA]
- Start date: 091999
 - End date: 082000
 - Qualification: Certificat of environmental expert level A
 - Organisation: This certificate gives access to assist companies to optimise their environmental situation. Level A is for the "most" risk prone companies.
 - Country: Belgium

Additional information

Publications

Many, on average 12 each year (up to now more than 200 in Focus Diagnostica and PROSTAATinfo, on the medical laboratory [Focus Diagnostica is not a peer reviewed magazine] and on cancer. 1. EAU_EANM_ESTRO_ESUR_SIOG Guidelines on Prostate Cancer_2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea_Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P. Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7. PMID: 33172724 2. EAU_EANM_ESTRO_ESUR_SIOG Guidelines on Prostate Cancer. Part II_2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, der Kwast THV, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea_Lager DE, der Poel HGV, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Mottet N. Eur Urol. 2021 Feb;79(2):263-282. doi: 10.1016/j.eururo.2020.09.046. Epub 2020 Oct 7. PMID: 33039206 3. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, Cumberbatch M, De Santis M, Tilki D, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Rouvière O, Pecanka J, Mason MD, Schoots IG, van Der Kwast TH, van Der Poel HG, Wiegel T, Willemse PM, Yuan Y, Lam TB, Cornford P, Mottet N. Eur Urol. 2019 Jun;75(6):967-987. doi: 10.1016/j.eururo.2018.10.011. Epub 2018 Oct 17. PMID: 30342843 4. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Lardas M, Liew M, van den Bergh RCN, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T, Henry AM, Bolla M, Briers E, Joniau S, Lam TB, Mason MD, Mottet N, van der Poel HG, Rouvière O, Schoots IG, Wiegel T, Willemse PM, Yuan CY, Bourke L. Eur Urol. 2017 Dec;72(6):869-885. doi: 10.1016/j.eururo.2017.06.035. Epub 2017 Jul 27. PMID: 28757301 5. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Fossati N, Willemse PM, Van den Broeck T, van den Bergh RCN, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S. Eur Urol. 2017 Jul;72(1):84-109. doi: 10.1016/j.eururo.2016.12.003. Epub 2017 Jan 24. PMID: 28126351 6. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D, De Santis M, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Mason M, Moris L, Schoots IG, van der Kwast T, van der Poel H, Wiegel T, Willemse PM, Rouvière O, Lam TB, Mottet N. Eur Urol Focus. 2020 Mar 15;6(2):231-234. doi: 10.1016/j.euf.2019.06.004. Epub 2019 Jun 24. PMID: 31248850 7. EAU_ESTRO_SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25. PMID: 27568654 8. EAU_EANM_ESTRO_ESUR_SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, Bjartell A, Bossi A, Briers E, Briganti A, Buddingh KT, Catto JWF, Coecchia M, Cox BW, Cumberbatch MG, Davies J, Davis NF, De Santis M, Dell'Oglio P, Deschamps A, Donaldson JF, Egawa S, Fankhauser CD, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet JP, Henry AM, Ingels A, Irani J, Lardas M, Liew M, Lin DW, Moris L, Omar MI, Pang KH, Paterson CC, Renard_Penna R, Ribal MJ, Roobol MJ, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots IG, Sedelaar JPM, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, van Leenders GJLH, Varma M, Violette PD, Wallis CJD, Wiegel T, Wilkinson K, Zattoni F, N'Dow JMO, Van Poppel H, Cornford P, Mottet N. Eur Urol. 2019 Dec;76(6):790-813. doi: 10.1016/j.eururo.2019.09.020. Epub 2019 Oct 3. PMID: 31587989 9. EAU_ESTRO_SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N. Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31. PMID: 27591931 10. Benefits and Risks of Primary Treatments for High_risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Moris L, Cumberbatch MG, Van den Broeck T, Gandaglia G, Fossati N, Kelly B, Pal R, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S, Grummet JP, Henry AM, Lam TBL, Lardas M, Liew M, Mason MD, Omar MI, Rouvière O, Schoots IG, Tilki D, van den Bergh RCN, van Der Kwast TH, van Der Poel HG, Willemse PM, Yuan CY, Konecny B, Dorff T, Jain S, Mottet N, Wiegel T. Eur Urol. 2020 May;77(5):614-627. doi: 10.1016/j.eururo.2020.01.033. Epub 2020 Mar 4. PMID: 32146018 11. Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91. van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM, Lam TB, Mason MD, Rouvière O, De Santis M, Wiegel T, Willemse PM, van Poppel H, Mottet N. Eur Urol. 2019 Feb;75(2):e23-e24. doi: 10.1016/j.eururo.2018.08.043. Epub 2018 Sep 17. PMID: 30237024 No abstract available. 12. European consensus on patient contact shielding. Hiles P, Gilligan P, Damilakis J, Briers E, Candela Juan C, Faj D, Foley S, Frijia G, Granata C, de Las Heras Gala H, Pauwels R, Sans Merce M, Simantirakis G, Vano E. Insights Imaging. 2021 Dec 23;12(1):194. doi: 10.1186/s13244-021-01085-4. PMID: 34939154 Free PMC article. 13. A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. Bates AS, Ayers J, Kostakopoulos N, Lumsden T, Schoots IG, Willemse PM, Yuan Y, van den Bergh RCN, Grummet JP, van der Poel HG, Rouvière O, Moris L, Cumberbatch MG, Lardas M, Liew M, Van den Broeck T, Gandaglia G, Fossati N, Briers E, De Santis M, Fanti S, Gillessen S, Oprea_Lager DE, Ploussard G, Henry AM, Tilki D, van der Kwast TH, Wiegel T, N'Dow J, Mason MD, Cornford P, Mottet N, Lam TBL. Eur Urol Oncol. 2021 Jun;4(3):405-423. doi: 10.1016/j.euo.2020.12.008. Epub 2021 Jan 8. PMID: 33423943 14. What radiologists need to know about patients' expectations: P.A.T.I.E.N.T.S C.A.R.E.R.S A.I.M.S. European Society of Radiology (ESR). Insights Imaging. 2022 Mar 22;13(1):53. doi: 10.1186/s13244-022-01184-w. PMID: 35316426 Free PMC article. 15. "TREXIT 2020": why the time to abandon transrectal prostate biopsy starts now. Grummet J, Gorin MA, Popert R, O'Brien T, Lamb AD, Hadaschik B, Radtke JP, Wagenlehner F, Baco E, Moore CM, Emberton M, George AK, Davis JW, Szabo RJ, Buckley R, Loblaw A, Allaway M, Kastner C, Briers E, Royce PL, Frydenberg M, Murphy DG, Wood HH. Prostate Cancer

Prostatic Dis. 2020 Mar;23(1):62-65. doi: 10.1038/s41391_020_0204_8. Epub 2020 Jan 13. PMID: 31932659 Free PMC article. Review. No abstract available. 16. Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. De Ruyscher D, Defraene G, Ramaekers BLT, Lambin P, Briens E, Stobart H, Ward T, Bentzen SM, Van Staa T, Azria D, Rosenstein B, Kerns S, West C. *Radiother Oncol.* 2016 Dec;121(3):440-446. doi: 10.1016/j.radonc.2016.11.003. Epub 2016 Dec 12. PMID: 27979370 Free PMC article. Review. 17. Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. Mottet N, De Santis M, Briens E, Bourke L, Gillessen S, Grummet JP, Lam TB, van der Poel HG, Rouvière O, van den Bergh RCN, Cornford P. *Eur Urol.* 2018 Mar;73(3):316-321. doi: 10.1016/j.eururo.2017.09.029. Epub 2017 Nov 2. PMID: 29103760 18. Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. *Eur Urol.* 2020;78:304-6. Prebiopsy MRI: Through the Looking Glass. van den Bergh RCN, Rouvière O, van der Kwast T; EAU_EANM_ESTRO_ESUR_SIOG Prostate Cancer Guidelines Panel. *Eur Urol.* 2020 Sep;78(3):310-313. doi: 10.1016/j.eururo.2020.06.005. Epub 2020 Jul 11. PMID: 32660749 No abstract available. 19. A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. Van den Broeck T, Oprea-Lager D, Moris L, Kailavasan M, Briens E, Cornford P, De Santis M, Gandaglia G, Gillessen Sommer S, Grummet JP, Grivas N, Lam TBL, Lardas M, Liew M, Mason M, O'Hanlon S, Pecanka J, Ploussard G, Rouvière O, Schoots IG, Tilki D, van den Bergh RCN, van der Poel H, Wiegel T, Willemse PP, Yuan CY, Mottet N. *Eur Urol.* 2021 Nov;80(5):531-545. doi: 10.1016/j.eururo.2021.04.028. Epub 2021 May 5. PMID: 33962808 Review. 20. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. Willemse PM, Davis NF, Grivas N, Zattoni F, Lardas M, Briens E, Cumberbatch MG, De Santis M, Dell'Oglio P, Donaldson JF, Fossati N, Gandaglia G, Gillessen S, Grummet JP, Henry AM, Liew M, MacLennan S, Mason MD, Moris L, Plass K, O'Hanlon S, Omar MI, Oprea-Lager DE, Pang KH, Paterson CC, Ploussard G, Rouvière O, Schoots IG, Tilki D, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TBL. *Eur Urol.* 2022 Apr;81(4):337-346. doi: 10.1016/j.eururo.2021.12.007. Epub 2021 Dec 31. PMID: 34980492 21. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. Beyer K, MacLennan SJ, Moris L, Lardas M, Mastris K, Hooker G, Greene R, Briens E, Omar MI, Healey J, Tripathi S, Gandaglia G, Venderbos LDF, Smith EJ, Björkqvist J, Asiiimwe A, Huber J, Roobol MJ, Zong J, Bjartell A, N'Dow J, Briganti A, MacLennan S, Van Helmerik M; PIONEER Consortium; EAU; LU; UNISR; Erasmus; UKE; TAU; KCL; EORTC; TTOP; ICHOM; ECP; ASSOC EISBM; ICL; Hyve; EAPM; PM; WI; UoA; TUD; Fraunhofer; UGOT; Radboud; IHE; Bayer AG; SANOFI; ASTELLAS; SAS; Janssen; IQVIA; eGF_eCancer; AstraZeneca; HelmHoltz. *Eur Urol Focus.* 2021 Sep;7(5):943-946. doi: 10.1016/j.euf.2021.09.008. Epub 2021 Oct 1. PMID: 34602368 22. Policy statement on multidisciplinary cancer care. European Partnership Action Against Cancer consensus group, Borrás JM, Albrecht T, Audisio R, Briens E, Casali P, Esperou H, Grube B, Hamoir M, Henning G, Kelly J, Knox S, Nabal M, Pierotti M, Lombardo C, van Harten W, Poston G, Prades J, Sant M, Travado L, Valentini V, van de Velde C, van den Bogaert S, van den Bulcke M, van Hoof E, van den Neucker I, Wilson R. *Eur J Cancer.* 2014 Feb;50(3):475-80. doi: 10.1016/j.ejca.2013.11.012. Epub 2013 Dec 6. PMID: 24321260 23. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briens E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N. *Eur Urol.* 2016 May;69(5):802-20. doi: 10.1016/j.eururo.2015.11.023. Epub 2015 Dec 12. PMID: 26691493 Review. 24. Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. Franco NR, Massi MC, Ieva F, Manzoni A, Paganoni AM, Zunino P, Veldeman L, Ost P, Fonteyne V, Talbot CJ, Rattay T, Webb A, Johnson K, Lambrecht M, Hausermans K, De Meerleer G, de Ruyscher D, Vanneste B, Van Limbergen E, Choudhury A, Elliott RM, Sperk E, Veldwijk MR, Herskind C, Avuzzi B, Noris Chiora B, Valdagni R, Azria D, Farcy_Jacquet MP, Brengues M, Rosenstein BS, Stock RG, Vega A, Aguado_Barrera ME, Sosa_Fajardo P, Dunning AM, Fachal L, Kerns SL, Payne D, Chang-Claude J, Seibold P, West CML, Rancati T; REQUITE Consortium Collaborators. *Radiother Oncol.* 2021 Jun;159:241-248. doi: 10.1016/j.radonc.2021.03.024. Epub 2021 Apr 8. PMID: 33838170 Free PMC article. 25. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briens E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O. *Eur Urol.* 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21. PMID: 28336078 Review. 26. Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. Lam TBL, MacLennan S, Plass K, Willemse PM, Mason MD, Cornford P, Donaldson J, Davis NF, Dell'Oglio P, Fankhauser C, Grivas N, Ingels A, Lardas M, Liew M, Pang KH, Paterson C, Omar MI, Zattoni F, Buddingh KT, Van den Broeck T, Cumberbatch MG, Fossati N, Gross T, Moris L, Schoots IG, van den Bergh RCN, Briens E, Fanti S, De Santis M, Gillessen S, Grummet JP, Henry AM, van der Poel HG, van der Kwast TH, Rouvière O, Tilki D, Wiegel T, N'Dow J, Van Poppel H, Mottet N. *Eur Urol.* 2019 Apr;75(4):699-702. doi: 10.1016/j.eururo.2018.11.009. Epub 2018 Nov 22. PMID: 30473433 No abstract available. 27. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Seibold P, Webb A, Aguado_Barrera ME, Azria D, Bourquier C, Brengues M, Briens E, Bultjijnck R, Calvo_Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning AM, Elliott RM, Fachal L, Farcy_Jacquet MP, Gabriele P, Garibaldi E, Gómez_Caamaño A, Gutiérrez_Enriquez S, Higginson DS, Johnson K, Lobato_Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein BS, De Ruyscher D, De Santis MC, Schäfer J, Schnabel T, Sperk E, Symonds RP, Stobart H, Taboada_Valladares B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West CML, Chang-Claude J; REQUITE consortium. *Radiother Oncol.* 2019 Sep;138:59-67. doi: 10.1016/j.radonc.2019.04.034. Epub 2019 May 27. PMID: 31146072 28. Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. Moris L, Gandaglia G, Vilaseca A, Van den Broeck T, Briens E, De Santis M, Gillessen S, Grivas N, O'Hanlon S, Henry A, Lam TB, Lardas M, Mason M, Oprea-Lager D, Ploussard G, Rouvière O, Schoots IG, van der Poel H, Wiegel T, Willemse PP, Yuan CY, Grummet JP, Tilki D, van den Bergh RCN, Cornford P, Mottet N. *Eur Urol Focus.* 2022 May;8(3):690-700. doi: 10.1016/j.euf.2021.05.009. Epub 2021 Jun 17. PMID: 34147405 Review. 29. Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. Lardas M, Grivas N, Debray TPA, Zattoni F, Berridge C, Cumberbatch M, Van den Broeck T, Briens E, De Santis M, Farolfi A, Fossati N, Gandaglia G, Gillessen S, O'Hanlon S, Henry A, Liew M, Mason M, Moris L, Oprea-Lager D, Ploussard G, Rouvière O, Schoots IG, van der Kwast T, van der Poel H, Wiegel T, Willemse PP, Yuan CY, Grummet JP, Tilki D, van den Bergh RCN, Lam TB, Cornford P, Mottet N. *Eur Urol Focus.* 2022 May;8(3):674-689. doi: 10.1016/j.euf.2021.04.020. Epub 2021 May 6. PMID: 33967010 Review. 30. External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. Rattay T, Seibold P, Aguado_Barrera ME, Altabas M, Azria D, Barnett GC, Bultjijnck R, Chang-Claude J, Choudhury A, Coles CE, Dunning AM, Elliott RM, Farcy_Jacquet MP, Gutiérrez_Enriquez S, Johnson K, Müller A, Post G, Rancati T, Reyes V, Rosenstein BS, De Ruyscher D, de Santis MC, Sperk E, Stobart H, Symonds RP, Taboada_Valladares B, Vega A, Veldeman L, Webb AJ, West CM, Valdagni R, Talbot CJ; REQUITE consortium. *Front Oncol.* 2020 Oct 30;10:575909. doi: 10.3389/fonc.2020.575909. eCollection 2020. PMID: 33216838 Free PMC article. 31. Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). Van der Weijst L, Aguado_Barrera ME, Azria D, Berkovic P, Boisselier P, Briens E, Bultjijnck R, Calvo_Crespo P, Chang-Claude J, Choudhury A, Defraene G, Demontois S, Dunning AM, Elliott RM, Ennis D, Faivre-Finn C, Franceschini M, Gutiérrez_Enriquez S, Herskind C, Higginson DS, Kerns SL, Johnson K, Mollà M, Lambrecht M, Ramos M, Rancati T, Rimmer A, Rosenstein BS, De Ruyscher D, Salem A, Sangalli C, Seibold P, Sosa_Fajardo P, Sperk E, Stobart H, Summersgill H, Surmont V, Symonds P, Taboada_Lorenzo B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML; REQUITE Consortium, Lievens Y. *Lung Cancer.* 2022 Apr;166:228-241. doi: 10.1016/j.lungcan.2022.03.010. Epub 2022 Mar 15. PMID: 35334417 32. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. van der Poel HG, van den Bergh RCN, Briens E, Cornford P, Govorov A, Henry AM, Lam TB, Mason MD, Rouvière O, De Santis M, Willemse PM, van Poppel H, Mottet N. *Eur Urol.* 2018 Jul;74(1):84-91. doi:

10.1016/j.eururo.2018.01.001. Epub 2018 Jan 17. PMID: 29373215 33. The correlation between pre_treatment symptoms, acute and late toxicity and patient_reported health_related quality of life in non_small cell lung cancer patients: Results of the REQUITE study. van der Weijst L, Azria D, Berkovic P, Boisselier P, Briers E, Bultijnck R, Chang_Claude J, Choudhury A, Defraene G, Demontois S, Elliott RM, Ennis D, Faivre_Finn C, Franceschini M, Giandini T, Giraldo A, Gutiérrez_Enriquez S, Herskind C, Higginson DS, Kerns SL, Johnson K, Lambrecht M, Lang P, Ramos M, Rancati T, Rimmer A, Rosenstein BS, De Ruyscher D, Salem A, Sangalli C, Seibold P, Sosa Fajardo P, Sperk E, Stobart H, Summersgill H, Surmont V, Symonds P, Taboada_Valladares B, Talbot CJ, Vega A, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML, Lievens Y; REQUITE consortium. Radiother Oncol. 2022 Oct 3;176:127_137. doi: 10.1016/j.radonc.2022.09.020. Online ahead of print. PMID: 36195214 34. Treatment time and circadian genotype interact to influence radiotherapy side_effects. A prospective European validation study using the REQUITE cohort. Webb AJ, Harper E, Rattay T, Aguado_Barrera ME, Azria D, Bourcier C, Brengues M, Briers E, Bultijnck R, Chang_Claude J, Choudhury A, Cicchetti A, De Ruyscher D, De Santis MC, Dunning AM, Elliott RM, Fachal L, Gómez_Caamaño A, Gutiérrez_Enriquez S, Johnson K, Lobato_Busto R, Kerns SL, Post G, Rancati T, Reyes V, Rosenstein BS, Seibold P, Seoane A, Sosa_Fajardo P, Sperk E, Taboada_Valladares B, Valdagni R, Vega A, Veldeman L, Ward T, West CM, Symonds RP, Talbot CJ; REQUITE Consortium. EBioMedicine. 2022 Oct;84:104269. doi: 10.1016/j.ebiom.2022.104269. Epub 2022 Sep 18. PMID: 36130474 Free PMC article. 35. Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. Kerns SL, Amidon Morlang A, Lee SM, Peterson DR, Marples B, Zhang H, Bylund K, Rosenzweig D, Hall W, De Ruyck K, Rosenstein BS, Stock RG, Gómez_Caamaño A, Vega A, Sosa_Fajardo P, Taboada_Valladares B, Aguado_Barrera ME, Parker C, Veldeman L, Fonteyne V, Bultijnck R, Talbot CJ, Symonds RP, Johnson K, Rattay T, Webb A, Lambrecht M, de Ruyscher D, Vanneste B, Choudhury A, Elliott RM, Sperk E, Herskind C, Veldwijk MR, Rancati T, Avuzzi B, Valdagni R, Azria D, Farcy Jacquet MP, Chang_Claude J, Seibold P, West C, Janelins M, Chen Y, Messing E, Morrow G; REQUITE Consortium. Radiother Oncol. 2022 Mar;168:75_82. doi: 10.1016/j.radonc.2022.01.014. Epub 2022 Jan 22. PMID: 35077710

Projects

European Association of Urology, Guidelines committee on prostate cancer, patient member

Memberships

Europa Uomo, Vice_Chair Us Too Belgium, Vice_Chair Chief editor of Focus Diagnostica Chief editor of PROSTAATInfo [Us Too Belgium magazine] AAAS (Us) member BMUC Belgian Multi Disciplinary Urological cancers Consult (founding member) EAU (European Association of Urology) ESMO (European Society for Medical Oncology)

Other Relevant Information